Studies have shown that tumours characterised by high infiltration of effector immune cells such as CD8+ T Cells and activation of immune checkpoints are considered to be ‘hot immune tumours’, which benefit highly from ICI treatments (Galon and Bruni, 2019; Liu and Sun, 2021). Here, CD8A is linked to neoplasm.